CAS: 212322-56-0; Ethyl 3-(3-Amino-4-(Methylamino)-N-(Pyridin-2-yl)Benzamido)Propanoate

相似化合物

429659-01-8 1771756-20-7 429659-01-8

上下游产品

CAS号429659-01-8 3-(4-(甲基氨基)-3-硝... | CAS号41263-74-5 4-甲氨基-3-硝基苯甲酸 | CAS号82357-48-0 3-硝基-4-甲胺基-苯甲酰氯 | CAS号1187067-71-5 4-(methylamine)... | CAS号96-99-1 4-氯-3-硝基苯甲酸 | CAS号872728-81-9 甲磺酸达比加群酯 | CAS号211915-06-9 达比加群酯 | CAS号1307233-94-8 达比加群酯中间体3 | CAS号211915-84-3 3-[[[2-[[(4-氰基苯... | CAS号872728-84-2 .beta.-丙氨酸, N-[...

4-氯-3-硝基苯甲酸置于氯化亚砜,Palladium 10% On Activated Carbon,甲酸铵,N,N-二异丙基乙胺体系中,用 乙醇,二氯甲烷,N,N-二甲基甲酰胺,甲苯 用作溶剂,化学反应 15.5H,反应生成3-[(3-氨基-4-甲基苯甲酰)吡啶-2基氨基]丙酸乙酯
参考文献:3-[(3-Amino-4-Methylaminobenzoyl Pyridin-2-yl)Amino]丙酸乙酯的新型一锅法合成
标题:3-[(3-Amino-4-Methylaminobenzoyl Pyridin-2-yl)Amino]丙酸乙酯的新型一锅法合成
摘要:达比加群酯(n-[2-{4-[n-(己氧羰基)脒基]苯基氨基甲基}-1甲基-1H-苯并咪唑-5-基羰基]-N-(2-吡啶基)-β-丙氨酸乙酯,9)是一种选择性,可逆和直接的凝血酶抑制剂;它已在临床上开发用于预防静脉血栓形成和心源性中风.1-3 据报道,制备达比加群酯的关键中间体 4,5 是 3-[(3-Amino-4-Methylaminobenzoyl)Pyridin-2-Yl-氨基]丙酸乙酯(6),从4-甲氨基-3-硝基苯甲酸(1)得到的总产率仅为25~50%(方案1).4-6
Doi:10.1080/00304948.2014.922383

专利信息

专利号:US-8378113-B2
优先权日:2008-06-16
标 题:Process for the manufacture of an intermediate in the synthesis of dabigatran
发明人：HEDDESHEIMER INGO; SCHOLZ ULRICH
权利人:BOEHRINGER INGELHEIM INT; HEDDESHEIMER INGO; SCHOLZ ULRICH
摘要:The invention relates to a process for the synthesis of the diamine of formula (1) an important intermediate in the synthesis of dabiagtran etexilate.

专利号:US-9533971-B2
优先权日:2012-10-29
标 题 :Process for the synthesis of dabigatran and its intermediates
发明人：PULLAGURLA MANIK REDDY; RANGISETTY JAGADEESH BABU; NANDAKUMAR MECHERIL VALSAN
权利人:BIOPHORE INDIA PHARMACEUTICALS PVT LTD; BIOPHORE INDIA PHARMACEUTICALS PVT LTD
摘要:The present invention describes an improved process for the preparation of Dabigatran Etexilate (Formula-VII) or it's pharmaceutically acceptable salt for the treatment of thrombosis, cardiovascular diseases etc. and intermediates involved in the synthesis.

专利号:US-9365544-B2
优先权日:2012-07-16
标题 :Process for the preparation of intermediates for the synthesis of Dabigatran Etexilate, and crystalline forms of said intermediates
发明人：HERNÀNDEZ GALLEGO SANTOS; MARQUILLAS OLONDRIZ FRANCISCO; POMARES MARCO MARTA
权利人:INTERQUIM SA
摘要:The present invention relates to new processes for the preparation of synthesis intermediate products useful in the preparation of Dabigatran Etexilate on an industrial scale. The invention also relates to new crystalline forms of intermediate products thus obtained.

专利号:US-9273030-B2
优先权日:2012-04-02
标题 :Process for the preparation of benzimidazole derivatives and salts thereof
发明人：THIRUMALAI RAJAN SRINIVASAN; ESWARAIAH SAJJA; RAGHURAM SURAPARAJU
权利人:MSN LAB PRIVATE LTD
摘要:Provided are novel salts of benzimidazole derivatives, preferably salts of benzimidazole derivatives which are useful intermediates in the synthesis of pure 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-yl-carboxylicacid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide and its salts.

专利号:US-9688657-B2
优先权日:2013-03-25
标题:Synthesis of dabigatran
发明人：PATKAR LAXMIKANT NARHARI; MONDKAR HARISH KASHINATH; AROTE NITIN DNYANESHWAR; PATIL SACHIN SHIVAJI; JADHAV TANAJI SHAMRAO; HAGAVANE NITIN NIVRUTTI; BHOPALKAR RAJESH GANPAT
权利人:USV PRIVATE LTD
摘要:The present invention relates to a process for preparation of Dabigatran etexilate or pharmaceutically acceptable salt thereof. The present invention relates to novel compounds, in particular Ethyl-3-{[(2-formyl-1-methyl-1H-benzimidazole-5-yl)carbonyl]-(2-pyridinyl) amino}propanoate and Ethyl-3-{[(2-dichloromethyl-1-methyl-1H-benzimidazole-5-yl)carbonyl]-(2-pyridinyl)amino}propanoate and process for preparation thereof. The present invention further relates to the use of these novel compounds in the preparation of Dabigatran etexilate or pharmaceutically acceptable salt thereof.

专利号:US-8471033-B2
优先权日:2008-06-16
标题 :Method for producing an intermediate product of dabigatran etexilate
发明人：FILSER CHRISTIAN; DERSCH WOLFGANG; HAMM RAINER; HAUSHERR ARNDT; KOCH GUNTER; SCHOLZ ULRICH; ZERBAN GEORG
权利人:FILSER CHRISTIAN; DERSCH WOLFGANG; HAMM RAINER; HAUSHERR ARNDT; KOCH GUNTER; SCHOLZ ULRICH; ZERBAN GEORG; BOEHRINGER INGELHEIM INT
摘要:The invention relates to a process for preparing the compound of formula 1 n na valuable intermediate product in the synthesis of the pharmaceutical active substance dabigatran etexilate.